Antiplatelet therapy, including aspirin, is recommended to lower the vascular risk in patients with intermittent claudication. Policosanol has increased walking distances in these patients, probably because of its antiplatelet effects, but the effect of shorter treatment has not been studied. This double-blind study compared the effects of policosanol 10 mg/d and aspirin 100 mg/d for 10 weeks on walking distances in claudicants. Thirty-nine patients were randomized to policosanol or aspirin. Walking distances on a treadmill were assessed before and after treatment. Policosanol significantly increased the initial and absolute claudication distances, while aspirin changed neither variable. Policosanol, not aspirin, significantly lowered serum low-density lipoprotein-cholesterol and total cholesterol while raising high-density lipoprotein-cholesterol. In conclusion, treatments of policosanol, not aspirin, for 10 weeks significantly increased walking distances, but modestly, in contrast with previous results. Therefore, the duration of treatments at the doses tested was too short for meaningful effects on the treadmill test.
Hirsch AT, Criqui MH, Treat-Jacobson D., et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA. 2001;286:1317-1324.
2.
Hiatt WRMedical treatment of peripheral arterial disease and claudication . N Engl J Med. 2001;344:1608-1621.
3.
Hankey GJ, Norman PE, Eikelboom JWMedical treatment of peripheral arterial disease. JAMA. 2006;295:547-553.
4.
Criqui MH, Fronek A., Barrett-Connor E., et al. The prevalence of peripheral arterial disease in a defined population . Circulation. 1985;71:510-515.
5.
Balkan B., Vray M., Eschwegp E.Epidemiology of peripheral arterial disease. J Cardiovasc Pharmacol. 1994;23:(suppl 3): 8-16.
6.
Howell MA, Colgan MP, Seeger RW, et al. Relationship of severity of lower limb peripheral vascular disease to mortality and morbidity: a six-year follow-up study. J Vasc Surg. 1989;9:691-697.
7.
Ogren M., Hedblad B., Isacsson SO, et al. Non-invasively detected carotid stenosis and ischaemic heart disease in men with leg arteriosclerosis. Lancet. 1993;342:1138-1141.
8.
Criqui MH, Denenberg JO, Langer RD, et al. The epidemiology of peripheral arterial disease: importance of identifying the population at risk. Vasc Med. 1997;2:221-226.
9.
Murabito JM, Evans JC, Nieto K., et al. Prevalence and clinical correlates of peripheral arterial disease in the Framingham Offspring Study. Am Heart J. 2002;143:961-965.
10.
Newman AB, Siscovick DS, Manolio TA, et al. Ankle-arm index as a marker of atherosclerosis in the cardiovascular health study. Circulation. 1993;88:837-845.
11.
Fowkes FGR , Leng GC, Lee AJ, et al. The ankle arm index as a predictor of cardiovascular events and death in general population. Abstracts of the 4th international conference on preventive cardiology. Can J Cardiol. 1997;13:(suppl):B268.
12.
Bowlin SJ, Medalie JH, Flocke SA, et al. Epidemiology of intermittent claudication in middle-aged men . Am J Epidemiol. 1994;140:418-430.
13.
Dormandy JA , Rutherford RBManagement of peripheral arterial disease (PAD): TASC Working Group. J Vasc Surg. 2000 ;31:S1-S296.
14.
Fowkes FGR , Housley E., Riemersma RA, et al. Smoking, lipids, glucose intolerance and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol. 1992;135:331-340.
15.
Lowe GDO , Fowkes FGR , Dawes J., et al. Blood viscosity, fibrinogen and activation of coagulation and leucocytes in peripheral arterial disease and the normal population in the Edinburgh Artery Study. Circulation. 1993;87:1915-1920.
16.
Ridker PM, Stampfer MJ, Rifai N.Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a) and standard cholesterol screening as predictors of peripheral arterial disease. JAMA . 2001;285:2481-2485.
17.
Hiatt WRPharmacologic therapy for peripheral arterial disease and claudication . J Vasc Surg. 2002;36:1283-1291.
18.
Hiatt WR, Krantz MJMasterclass series in peripheral arterial disease. Antiplatelet therapy for peripheral arterial disease and claudication. Vasc Med . 2006;11: 55-60.
19.
Clagett GP, Sobel M., Jackson MR, et al. Antithrombotic therapy in peripheral arterial occlusive disease . The seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest. 2004;126:609S-626S.
20.
Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324:71-86.
21.
Beebe HG, Dawson DL, Cutler BS, et al. A new pharmacologic treatment for intermittent claudication: results of a randomized, multicenter trial. Arch Intern Med . 1999;159:2041-2050.
22.
Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med. 2000;109:523-530.
23.
National Cholesterol Education Program (Adult Treatment Panel III).Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486-2497.
24.
Mohler ER, Hiatt WR, Creager MA; for the study investigators. Cholesterol reduction with atorvastatin improves walking distance in patients with peripheral arterial disease. Circulation2003;108:1481.
25.
Mondillo S. , Ballo P., Barbati R., et al. Effects of simvastatin on walking performance and symptoms of intermittent claudication in hypercholesterolemic patients with peripheral vascular disease. Am J Med. 2003;114:359-364.
26.
Aronow WS, Nayak D., Woodworth S., Ahn C.Effect of simvastatin versus placebo on treadmill exercise time until the onset of intermittent claudication in older patients with peripheral arterial disease at six months and at one year after treatment. Am J Cardiol. 2003;92:711-712.
27.
McDermott M. , Guralnik J., Greenland P., et al. Statin use and leg functioning in patients with and without lower-extremity peripheral arterial disease. Circulation. 2003;107:757.
28.
Mas R.Policosanol. Drugs Future. 2000;25:569-586.
29.
Pons P., Rodríguez M., Robaina C., et al. Effects of successive dose increases of policosanol on the lipid profile of patients with type II hypercholesterolemia and tolerability to treatment. Int J Clin Pharmacol Res. 1994; XIV:27-33.
30.
Torres O., Agramonte AJ, Illnait J., et al. Treatment of hypercholesterolemia in NIDDM with policosanol . Diabetes Care. 1995;18:393-397.
31.
Campilongo R., Sandini P., Feldman R., et al. Eficacia, seguridad y tolerabilidad del policosanol en pacientes argentinos con hipercolesterolemia tipo II. Estudio abierto. La Prensa Médica Argentina. 1996;83:665-672.
32.
Ortensi G., Gladstein H., Valli H., Tesone PAA comparative study of policosanol versus simvastatin in elderly patients with hypercholesterolemia. Curr Ther Res. 1997;58:390-401.
33.
Prat H., Roman O., Pino E.Efecto comparativo del policosanol con dos inhibidores de la HMGCoA reductasa en el tratamiento de la Hipercolesterolemia Tipo II. Rev Med Chile. 1999;127:286-294.
34.
Alcocer A., Fernández L., Campos E., Más R.A comparative study of policosanol vs acipimox in patients with type II hypercholesterolemia . Int J Tissue React. 1999;XXI:57-64.
35.
Nikitin IP, Stepchenko NV, Gratsianski NA, et al. Results of the multicenter controlled study of the hypolipidemic drug polycosanol in Russia. Tter Arkh. 2000 ;72:7-10.
36.
Mirkin A., Mas R., Martinto M., et al. Efficacy and tolerability of policosanol in hypercholesterolemic postmenopausal women. Int J Clin Pharmacol Res. 2001;XXI:31-42.
37.
Figuera SR, Soto I., Lara A., et al. Estudio comparativo de la eficacia y tolerancia del policosanol en pacientes con hipercolesterolemia Tipo II. Arch Venezol Farmacol Terap. 2001;20:88-91.
38.
Moreno FL, Lagomasino AL, Ramírez M., et al. Utilidad del policosanol en pacientes obesos sometidos a revascularización miocárdica quirúrgica. 4th virtual congress of cardiology2005.
39.
Canetti M., Morera M., Illnait J., et al. A two-year study on the efficacy and tolerability of policosanol in patients with type II. Int J Clin Pharmacol Res. 1995;XV:159-165.
40.
Batista JF, Stusser RJ, Padrón R., et al. Functional improvement in coronary artery disease after 20 month of lipid-lowering therapy with policosanol. Adv Ther. 1996;13:137-148.
41.
Castaño G., Mas R., Fernández J., et al. Effects of policosanol in older patients with hypertension and type II hypercholesterolemia. Drugs R D. 2002 ;3:159-172.
42.
Arruzazabala ML, Carbajal D., Más R. et al. Effects of policosanol on platelet aggregation in rats. Thromb Res. 1992;69:321-327.
43.
Arruzazabala ML, Carbajal D., Molina V., Valdés S., et al. Estudio farmacológico de la interacción entre el policosanol y la aspirina en animales de experimentación. Rev Iberoam Tromb Hemost. 1992;5:17-20.
44.
Scazziota A. , Pons S., Altman R.Efecto del policosanol sobre la función de las plaquetas en voluntarios sanos. Rev Iberoam Tromb Hemost . 1996;9:58-62.
45.
Carbajal D. , Arruzazabala ML, Valdés S., et al. Effect of policosanol on platelet aggregation and serum levels of arachidonic acid metabolites in healthy volunteers . Prostag Leuk Ess Fatty Acids. 1998;58:61-64.
46.
Arruzazabala ML, Molina V., Mas R., et al. Antiplatelet effects of policosanol 20 and 40 mg/d in healthy volunteers and dyslipidemic patients. Clin Exp Pharmacol Physiol. 2002 ;29:891-897.
47.
Castaño G., Fernández L., Mas R., et al. Comparison of the effects of policosanol and atorvastatin on lipid profile and platelet aggregation on patients with dyslipidemia and type 2 diabetes mellitus. Clin Drug Invest. 2003 ;23:639-650.
48.
Castaño G., Más R., Fernández L., et al. A double-blind placebo-controlled study of the effects of policosanol in patients with intermittent claudication. Angiology. 1998;50:123-130.
49.
Castaño G., Mas R., Fernández L., Gámez R., Illnait J., Fernández J.A long-term study of policosanol in the treatment of intermittent claudication . Angiology. 2001;52:115-125.
50.
Castaño G., Mas R., Fernández L., et al. Effects of policosanol and lovastatin in patients with intermittent claudication: a double-blind comparative pilot study. Angiology . 2003;54:25-38.
51.
Castaño G., Mas R., Gámez R., Fernández L., Illnait J.Effects of policosanol and ticlopidine in patients with intermittent claudication: a double-blinded pilot comparative study. Angiology . 2004;55:361-371.
52.
Heidrich H. , Allenberg J., Cachovan M., et al. Guidelines for therapeutic studies on peripheral arterial occlusive disease in Fontaine stages II-IV. Vasa. 1992;21:339-343.
53.
Ciocon JO, Galindo-Ciocon D., Galindo DJA comparison between aspirin and pentoxifylline in relieving claudication due to peripheral vascular disease in the elderly. Angiology . 1997;48:237-240.
54.
Gotto A., Assmann G., Carmena R., et al. The International Lipid Information Bureau (ILIB): Lipid Handbook for Clinical Practice. Blood Lipids and Coronary Heart Disease , 2nd ed. New York, NY: International Lipid Information Bureau; 2000.
55.
Tofler GH, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med. 1987;316: 1514-1518.
56.
Seigler L., Wu T.Separation of serum high-density lipoprotein for cholesterol determination: ultracentrifugation vs precipitation with sodium phosphotungstate and magnesium chloride. Clin Chem. 1981;27:838-841.
57.
Friedewald WT, Levy RI, Friederickson SDEstimation of the concentration of low-density lipoprotein cholesterol in plasma without of the preparative ultracentrifugue . Clin Chem. 1972;18:499-502.
58.
Naranjo CA, Busto U., Sellers EM, et al. A method for estimating the probability of adverse drug reactions . Clin Pharmacol Ther. 1981;30:239-245.
59.
Comerota AJEffect on platelet function of cilostazol, clopidogrel, and aspirin, each alone or in combination. Atheroscler Suppl . 2005;6:13-19.
60.
Allegra C., Pollari G., Carioti B., Sardina M.Thrombin and platelet inhibition with low-dose calcium-heparin in comparison with ASA in patients with peripheral arterial occlusive disease at Leriche-Fontaine IIb class. Int J Clin Pharmacol Ther. 1994 ;32:646-651.
61.
Pedersen TR , Kjekshus J., Pyorala K., et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol. 1998;81:333-335.
62.
Blankenhorn DH, Azen SP, Crawford DW, et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation. 1991;83:438-447.
63.
Chen JT, Wesley R., Shamburek RD, et al. Meta-analysis of natural therapies for hyperlipidemia: plant sterols and stanols versus policosanol. Pharmacotherapy. 2005;25:171-183.
64.
Greyling A. , De Witt C., Oosthuizen W., Jerlin JCEffects of a policosanol supplement on serum lipid concentrations in hypercholesteroleaemic and homozygous familial hypercholesterolemic subjects. Br J Nutr. 2006;95:968-975.
65.
Berthold HK , Unverdoben S., Degenhardt R., et al. Effect of policosanol on lipid levels among patients with hypercholesterolemia or combined hyperlipidemia: a randomized controlled-trial. JAMA. 2006;295:2262-2269.
66.
Cubbedu LX, Cubbedu RJ, Heimowitz T., et al. Comparative lipid-lowering effects of policosanol and atorvastatin: a randomized, parallel, double-blind, placebo-controlled trial. Am Heart J. 2006;152:982-985.
67.
Dulin MF, Hatcher LF, Sasser HC, Barringer TAPolicosanol is ineffective in the treatment of hypercolesterolemia: a randomized, controlled trial. Am J Clin Nutr. 2006;84:1543-1548.
68.
Wright CM, Zieike JC, Whayne TFPolicosanol, an aliphatic alcohol sugarcane derivative. Use in patients intolerant or inadequately responsive to statin therapy. Int J Angiol . 2004;13:173-175.
69.
Singh DK, Li L., Porter TDPolicosanol inhibits cholesterol synthesis in hepatoma cells by activation of AMP-kinases. J Pharmacol Exp Ther. 2006 ;106:107-144.
70.
Krusius T., Hirvonen J., Vahtera E., Kala R.Short-term aspirin treatment does not reduce plasma fibrinogen concentration in young healthy adults. Thromb Res. 1994;75:653-656.
71.
Hampton KK, Cerletti C., Loizou LA, et al. Coagulation, fibrinolytic and platelet function in patients on long-term therapy with aspirin 300 mg or 1,200 mg daily compared with placebo . Thromb Haemost. 1990;64:17-20.
72.
Woodward M. , Lowe GDO , Francis LmaMA; for the CADET study investigators. A randomized comparison of the effects of aspirin and clopidogrel on thrombotic risk factors and C-reactive protein following myocardial infarction: the CADET trial. J Thromb Haemost. 2004;2:1934-1940.
